References
- Hayes S, Dunne A, Smart T, Davism J. Interpretation and optimization of the dissolution specifications for a modified release product with an in-vivo in-vitro correlation (IVIVC). J Pharm Sci 2004;93:571–81
- Nishit BM, Andrew L, Elizabeth L, et al. Application of in vitro–in vivo correlations (IVIVC) in setting formulation release specifications. Biopharm Drug Dispos 2000;21:321–6
- Mirza T, Bykadi, SA, Ellison CD, et al. Use of in vitro–in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices. Pharm Res 2013;30:179–90
- Hodjegan RA, Shiran MR, Tucker GT, et al. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. Drug Dev Ind Pharm 2002;28:533–43
- Emara LH, El-Menshawi BS, Estefan MY. In vitro--in vivo correlation and comparative bioavailablity of vincamine in prolonged-release preparations. Drug Dev Ind Pharm 2000;26:243–51
- Food and Drug Administration. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations; September 1997. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070239.pdf [last accessed 15 Jan 2013]
- Gaynor C, Dunne A, Davis J. A comparison of the prediction accuracy of two IVIVC modeling techniques. J Pharm Sci 2008;97:3422–32
- Madden FN, Godfrey KR, Chappell MJ, et al. A comparison of six deconvolution techniques. J Pharmacokinet Biopharm 1996;24:283–99
- Gillespie WR. Convolution-based approaches for in vivo--in vitro correlation modeling. Adv Exp Med Biol 1997;423:53–65
- In-vitro and in-vivo evaluation of dosage forms. USP 30, chapter, 1088. United State Pharmacopeial Convention, Inc.; 2007:532–8
- Qureshi SA. In vitro--in vivo correlation (IVIVC) and determining drug concentrations in blood from dissolution testing -- a simple and practical approach. Open Drug Deliv J 2010;4:38–47
- Smolen VF, Erb RJ. Predictive conversion of in-vitro dissolution data into in-vivo drug response versus time profiles exemplified for plasma level of warferin. J Pharm Sci 1977;66:297–304
- Langenbucher F. Numerical convolution/deconvolution as a tool for correlating in-vitro with in-vivo drug availbility. Pharm Ind 1982;44:1166–72
- Bartlett KA. New medication for fibromyalgia: milnacipran. Pharmacother Update 2009;12. Available from: http://www.clevelandclinicmeded.com/medicalpubs/pharmacy/pdf/Pharmacotherapy_XII-4.pdf [last accessed 12 Jan 2013]
- Kranzler JD, Gendreau RM. Role and rational for use of milnacipran in the management of fibromyalgia. Neuropsychiatr Dis Treat 2010;6:197–208
- Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharm 2002;1:25–35
- Parejiya PB, Barot BS, Patel HK, et al. Innovation of novel ‘Tab in Tab’ system for release modulation of Milnacipran HCl: optimization, formulation, and in-vitro investigations. Drug Dev Ind Pharm 2013;39:1851–63
- Australian Public Assessment Report for Milnacipran, AusPAR Joncia Milnacipran Pierre Fabre Medicament Australia Pty Ltd; 2012:78–82. Available from: http://www.tga.gov.au/auspar/auspar-milnacipran-120124.htm [last accessed 20 Oct 2012]
- Bendas ER. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride. Arch Pharm Res 2009;32:1317–29